

# Sarcomatrix to Attend CureDuchenne FUTURES Conference 2024

RENO, NV, UNITED STATES, May 23, 2024 /EINPresswire.com/ --

Sarcomatrix Therapeutics Corp. is thrilled to announce its participation in the upcoming CureDuchenne FUTURES

National Conference, taking place from May 23 to May 26, 2024, at the JW Marriott Orlando, Grande Lakes, located at 4040 Central Florida Pkwy, Orlando, FL 32837.

SARCOMATRIX  
Saving Lives by Restoring Muscles

The CureDuchenne FUTURES National Conference is an esteemed annual event dedicated to providing education, fostering connections, and instilling hope within the Duchenne [muscular dystrophy](#) community. This year's conference promises to be transformative, focusing on the latest advancements in Duchenne research and featuring engaging sessions designed to inspire and energize attendees. Alongside insightful presentations and discussions, participants can look forward to a lively social atmosphere, complete with exciting dance activities.

“

Our researchers at Sarcomatrix have developed groundbreaking oral medications with the potential to benefit everyone living with muscular dystrophy.”

*David Craig, CEO*

Sarcomatrix is committed to advancing potential

treatments for Duchenne muscular dystrophy through rigorous pre-clinical studies, with plans to initiate human trials as soon as feasibly possible. To support these crucial efforts, the company is actively seeking additional funding.

About Sarcomatrix Therapeutics Corp.

At Sarcomatrix, we harness the power of science to develop therapies that significantly enhance and extend lives. We are dedicated to leading the way in quality, safety, and value in the discovery and development of groundbreaking medicines. Our mission is to make a meaningful impact on everyone who depends on us. For the latest updates and information vital to investors, visit our website at [www.Sarcomatrix.com](http://www.Sarcomatrix.com). Stay connected with us on X at @Sarcomatrix and @SarcomatrixNews, LinkedIn at /company/sarcomatrix, YouTube, and Facebook at [www.facebook.com/sarcomatrix](http://www.facebook.com/sarcomatrix).

## Support Sarcomatrix

Sarcomatrix has launched an equity crowdfunding campaign on StartEngine. To learn more, visit [www.startengine.com/offering/sarcomatrix](http://www.startengine.com/offering/sarcomatrix). Our initiative aims to accelerate the development of promising drug treatments for muscle diseases. We invite investors to join our team and help drive advancements in medical treatments for conditions affecting millions. Be part of our mission to shape the future of muscle disease therapy and healthcare innovation.

### Media Contact:

MediaRelations@Sarcomatrix.com

+1 (775) 525-1795

### Investor Contact:

IR@Sarcomatrix.com

Source: Sarcomatrix® Therapeutics, Corp.

David Craig

Sarcomatrix Therapeutics Corp.

+1 415-246-3311

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[Instagram](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/714026920>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.